GLP-1 treatment is not an established replacement for eating-disorder care. In one small randomized trial involving 27 adults with binge-eating disorder, liraglutide did not significantly outperform placebo on the primary binge-episode outcome. Weight loss and recovery from an eating disorder are different outcomes. [1]
If you have a current or past eating disorder, tell the prescriber before starting or escalating treatment. This is relevant at any body size. NIMH explains that people with eating disorders may be underweight, average weight, or overweight, and can be medically unwell despite appearing healthy. [2]
What the small trial can actually tell us
The liraglutide trial lasted 17 weeks. Both groups reported fewer binge episodes. Remission rates of 44% with liraglutide and 36% with placebo did not differ significantly, although weight loss was greater with liraglutide. A pharmacy dispensing error was an important limitation. [1]
These findings justify further study, not a claim that appetite suppression treats every eating disorder. They also cannot establish safety for anorexia nervosa, bulimia nervosa, or avoidant restrictive food intake disorder. The diagnoses involve different patterns and risks.
Our article on how GLP-1 treatment changes food intake describes an appetite outcome. It should not be read as a measure of psychological recovery or nutritional adequacy.
Why a quieter appetite can be complicated
A specialist review concludes that evidence is insufficient to establish how GLP-1 medicines should be used in eating-disorder populations. It highlights uncertainty about whether they may improve, worsen, or contribute to symptoms. [3] A person feeling less driven to eat may welcome the change, while another may find that it reinforces restrictive behavior.
The useful question is not simply whether you feel less hungry. It is whether you can nourish yourself reliably and whether thoughts or behaviors around food are becoming more distressing or rigid. Those changes warrant discussion with a qualified clinician rather than praise for a lower number on the scale.
What to tell your care team
Share any history of eating-disorder treatment, recurrent loss-of-control eating, purging, fear-driven food avoidance, or compulsive exercise. Explain changes that began after starting treatment, including difficulty eating enough or anxiety about eating despite needing nourishment. NIMH describes these kinds of behaviors as reasons for professional assessment. [2]
Medication-related nausea can complicate the picture without automatically meaning a new eating disorder. Our guide to why GLP-1 drugs cause nausea discusses the physical symptom. A clinician should consider both physical intolerance and the emotional or behavioral response to it.
Coordinate treatment instead of choosing between concerns
An eating-disorder-informed clinician, prescriber, and dietitian can help assess whether treatment fits your situation and what monitoring is needed. NIMH describes care that can include psychotherapy, nutrition support, and medical monitoring. [2] Do not change medication solely because an online story sounds similar to yours.
Activity should support health and function, not become punishment for eating. Our exercise guide uses general health goals rather than calorie-compensation targets. Similarly, vitamins and supplements cannot replace adequate food or specialist assessment.
What this evidence cannot answer yet
Small studies cannot tell us which individuals will improve, who may worsen, or how risk changes over years. Larger weight-loss trials are not interchangeable with trials designed to measure eating-disorder recovery. Future studies need to assess eating behavior, nutritional health, distress, and functioning, alongside weight.
If you are struggling now, you do not need to wait for that research to ask for help. Tell your primary care clinician or existing treatment team what has changed and ask for an eating-disorder assessment.